Brief: Bicara Therapeutics Announces Phase 3 Optimal Dose And Provides 2026 Corporate Outlook
12/01/2026 13:02
Jan 12 (Reuters) - Bicara Therapeutics Inc BCAX.O: BICARA THERAPEUTICS ANNOUNCES PHASE 3 OPTIMAL DOSE AND PROVIDES 2026 CORPORATE OUTLOOK BICARA THERAPEUTICS - EXPECTS TO ACHIEVE SUBSTANTIAL ENROLLMENT IN FORTIFI-HN01 IN 2026 TO ENABLE INTERIM ANALYSIS IN MID-2027 BICARA THERAPEUTICS INC - ANTICIPATES MULTIPLE DATA READOUTS IN 2026 FOR FICERAFUSP ALFA Source text: ID:nGNX4D2nGr Further company coverage: BCAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bicara Therapeutics
See all newsBrief: Bicara Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Bicara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Bicara Therapeutics Appoints Ryan Cohlhepp As President & CEO Effective January 2027
Brief: Bicara Therapeutics Announces Appointments Of Jeremy Bender And Christy Oliger To Board Of Directors